- Who We Are
- Our Focus
- Clinical Programs
- Healthcare Professionals
Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast, including the exclusive right to commercialize any resulting products.
In December 2019, Arcutis exercised its option under a 2018 License Agreement with Jiangsu Hengrui Medicine Co., Ltd. of China (Hengrui) for an exclusive license to the active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), for all topical dermatological uses in the United States, Canada, Europe and Japan. Under the license, Arcutis has exclusive right to commercialize any resulting products in these territories. Arcutis plans to develop ARQ-252 for hand eczema and other inflammatory dermatoses.